HRP20231608T1 - Derivati piridinil sulfonamida, njihovi farmaceutski pripravci i njihove uporabe - Google Patents
Derivati piridinil sulfonamida, njihovi farmaceutski pripravci i njihove uporabe Download PDFInfo
- Publication number
- HRP20231608T1 HRP20231608T1 HRP20231608TT HRP20231608T HRP20231608T1 HR P20231608 T1 HRP20231608 T1 HR P20231608T1 HR P20231608T T HRP20231608T T HR P20231608TT HR P20231608 T HRP20231608 T HR P20231608T HR P20231608 T1 HRP20231608 T1 HR P20231608T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- group
- heterocyclyl
- compound
- optionally substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- DWJMBQYORXLGAE-UHFFFAOYSA-N pyridine-2-sulfonamide Chemical class NS(=O)(=O)C1=CC=CC=N1 DWJMBQYORXLGAE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 14
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000002393 azetidinyl group Chemical group 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- -1 1-(cyclopropylcarbonyl)-piperidin-4-yl Chemical group 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (20)
1. Spoj, naznačen time, da je predstavljen formulom (I)
[image]
gdje
prsten A se bira iz skupine koju čine:
[image]
R1 se bira iz skupine koju čine H, F, Cl, Br, CN, -OH, C1-4-alkil, -O-(C1-4-alkil), -(CH2)m-COOH, -(CH2)m-C(=O)-O-(C1-4-alkil), -C(=O)-heterociklil, -(CH2)m-C(=O)-NH2, -(CH2)m-C(=O)-NH-(C1-4-alkil), -(CH2)m-C(=O)-N(C1-4-alkil)2, -C(=O)-NH-C3-6-cikloalkil, -C(=O)-NH-heterociklil, -(CH2)m-NH-C(=O)-(C1-3-alkil), -N(C1-3-alkil)-C(=O)-(C1-4-alkil), -N(C1-3-alkil)-C(=O)-NH2, -NH-C(=O)-NH-(C1-4-alkil), heterociklil i fenil,
pri čemu je svaka alkil skupina ili podskupina opcionalno supstituirana s jednim ili više F atoma ili s jednom OH ili -O-(C1-3-alkil) skupinom; i
pri čemu se svaki heterociklil bira iz skupine koju čine azetidinil, imidazolidinil, piperidinil, tetrahidropiranil i morfolinil, i opcionalno je supstituiran s jednom ili dvije skupine neovisno odabrane iz skupine koju čine okso, C1-3-alkil, -C(=O)-CH3 i -C(=O)-ciklopropil; i
gdje, višestruki R1 mogu biti isti ili različiti, ako n jest 2; i
n je cijeli broj odabran od 1 i 2; i
m je cijeli broj odabran od 0, 1 i 2; i
pri čemu u bilo kojoj definiciji koja je prethodno navedena, ako nije drugačije određeno, bilo koja alkil skupina ili podskupina može biti razgranatog lanca ili ravnolančana i opcionalno je supstituirana s jednim ili više F atoma,
ili njegova sol.
2. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da
R1 se bira iz skupine koju čine:
H, F, Cl, -OH, C1-4-alkil, -O-(C1-2-alkil), -(CH2)m-COOH, -(CH2)m-C(=O)-O-(C1-2-alkil), -C(=O)-heterociklil, -(CH2)m-C(=O)-NH2, -(CH2)m-C(=O)-NH-(C1-4-alkil), -(CH2)m-C(=O)-N(CH3)(C1-3-alkil), -C(=O)-NH-ciklopropil, -C(=O)-NH-heterociklil, -(CH2)m-NH-C(=O)-(C1-3-alkil), -N(C1-2-alkil)-C(=O)-(C1-2-alkil), -N(C1-2-alkil)-C(=O)-NH2, -NH-C(=O)-NH-(C1-2-alkil), heterociklil i fenil,
pri čemu je svaka alkil skupina ili podskupina opcionalno supstituirana s 1 do 3 F atoma ili s jednom OH ili -O-(C1-2-alkil) skupinom; i
pri čemu se svaki heterociklil bira iz skupine koju čine azetidinil, imidazolidinil, piperidinil, tetrahidropiranil i morfolinil, i opcionalno je supstituiran s jednom ili dvije skupine neovisno odabrane iz skupine koju čine okso, C1-2-alkil, -C(=O)-CH3 i -C(=O)-ciklopropil; i
pri čemu m je 0 ili 1; i
gdje, višestruki R1 mogu biti isti ili različiti, ako n jest 2;
ili njegova sol.
3. Spoj formule (I) prema patentnom zahtjevu 2, naznačen time, da
R1 se bira iz skupine koju čine:
H, F, -OH, -CH3, -CF3, -O-CH3, -COOH, -(CH2)m-C(=O)-O-CH3, -(CH2)m-C(=O)-NH2, -C(=O)-NH-(C1-3-alkil), -(CH2)-C(=O)-N(CH3)2, -(CH2)-C(=O)-N(CH3)(CH2CH3), -C(=O)-NH-ciklopropil, 1-(ciklopropilkarbonil)-piperidin-4-il i 3-metil-2-okso-imidazolidin-1-il,
pri čemu je svaka etil skupina ili podskupina opcionalno supstituirana na poziciji 2 s jednim F atomom, jednom OH ili jednom -O-CH3 skupinom; i
pri čemu je svaka propil skupina ili podskupina opcionalno supstituirana na poziciji 2 ili 3 s 1 do 3 F atoma; i
gdje m je 0 ili 1; i
pri čemu, ako n je 2, višestruki R1 mogu biti isti ili različiti i druga R1 skupina se bira iz skupine koju čine F, CH3, CF3 i fenil;
ili njegova sol.
4. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da
prsten A je
[image]
R1 se bira iz skupine koju čine H, F, -OH, C1-4-alkil, -O-(C1-4-alkil), -(CH2)m-COOH, -(CH2)m-C(=O)-O-(C1-4-alkil), -C(=O)-heterociklil, -(CH2)m-C(=O)-NH2, -(CH2)m-C(=O)-NH-(C1-4-alkil), -(CH2)m-C(=O)-N(C1-4-alkil)2, -C(=O)-NH-C3-6-cikloalkil, -C(=O)-NH-heterociklil, -(CH2)m-NH-C(=O)-(C1-3-alkil), -N(C1-3-alkil)-C(=O)-(C1-4-alkil), -N(C1-3-alkil)-C(=O)-NH2, -NH-C(=O)-NH-(C1-4-alkil), heterociklil i fenil,
pri čemu je svaka alkil skupina ili podskupina opcionalno supstituirana s jednim ili više F atoma ili s jednom OH ili -O-(C1-3-alkil) skupinom; i
pri čemu se svaki heterociklil bira iz skupine koju čine azetidinil, imidazolidinil, piperidinil, tetrahidropiranil i morfolinil, i opcionalno je supstituiran s jednom ili dvije skupine neovisno odabrane iz skupine koju čine okso, C1-3-alkil, -C(=O)-CH3 i -C(=O)-ciklopropil; i
gdje, višestruki R1 mogu biti isti ili različiti, ako n jest 2; i
n je cijeli broj odabran od 1 i 2; i
m je cijeli broj odabran od 0 i 1;
ili njegova sol.
5. Spoj formule (I) prema patentnom zahtjevu 4, naznačen time, da
R1 se bira iz skupine koju čine:
H, -OH, C1-2-alkil, -O-(C1-2-alkil), -(CH2)m-COOH, -(CH2)m-C(=O)-O-(C1-2-alkil), -C(=O)-heterociklil, -(CH2)m-C(=O)-NH2, -(CH2)m-C(=O)-NH-(C1-4-alkil), -(CH2)m-C(=O)-N(C1-2-alkil)2, -C(=O)-NH-C3-6-ciklopropil, -C(=O)-NH-heterociklil, -(CH2)m-NH-C(=O)-(C1-3-alkil), -N(CH3)-C(=O)-(C1-2-alkil), -N(CH3)-C(=O)-NH2, -NH-C(=O)-NH-(C1-3-alkil), heterociklil i fenil,
pri čemu je svaka alkil skupina ili podskupina opcionalno supstituirana s 1 do 3 F atoma ili s jednom OH ili -O-CH3 skupinom; i
pri čemu se svaki heterociklil bira iz skupine koju čine azetidinil, imidazolidinil, tetrahidropiranil i morfolinil, i opcionalno je supstituiran s jednom ili dvije skupine neovisno odabrane iz skupine koju čine okso, C1-3-alkil i -C(=O)-CH3;
i
gdje, ako n je 2, višestruki R1 mogu biti isti ili različiti, i druga R1 skupina se bira iz skupine koju čine CH3, CF3 i fenil;
ili njegova sol.
6. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da
prsten A je
[image]
R1 se bira iz skupine koju čine H, F, Cl, -OH, -O-(C1-4-alkil), -C(=O)-heterociklil, -(CH2)m-C(=O)-NH2, -(CH2)m-C(=O)-NH-(C1-4-alkil), -(CH2)m-C(=O)-N(C1-4-alkil)2, -(CH2)m-NH-C(=O)-(C1-3-alkil) i -N(C1-3-alkil)-C(=O)-(C1-4-alkil),
pri čemu je svaka alkil skupina ili podskupina opcionalno supstituirana s jednim ili više F atoma ili s jednom OH ili -O-(C1-3-alkil) skupinom; i
pri čemu se svaki heterociklil bira iz skupine koju čine azetidinil, imidazolidinil, piperidinil, tetrahidropiranil i morfolinil, i opcionalno je supstituiran s jednom okso ili C1-3-alkil skupinom; i
gdje, ako n je 2, višestruki R1 mogu biti isti ili različiti i druga R1 skupina jest F; i
n je cijeli broj odabran od 1 i 2; i
m je cijeli broj odabran od 0 i 1;
ili njegova sol.
7. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da
prsten A je
[image]
R1 se bira iz skupine koju čine H, -(CH2)m-COOH, -(CH2)m-C(=O)-O-(C1-4-alkil), -C(=O)-heterociklil, -(CH2)m-C(=O)-NH2, -(CH2)m-C(=O)-NH-(C1-4-alkil) i -(CH2)m-C(=O)-N(C1-4-alkil)2,
pri čemu je svaka alkil skupina ili podskupina opcionalno supstituirana s jednim ili više F atoma ili s jednom OH ili -O-(C1-3-alkil) skupinom; i
pri čemu se svaki heterociklil bira iz skupine koju čine azetidinil, imidazolidinil, piperidinil, tetrahidropiranil i morfolinil, i opcionalno je supstituiran s jednom okso ili C1-3-alkil skupinom; i
gdje, višestruki R1 mogu biti isti ili različiti, ako n jest 2; i
n je 1; i
m je cijeli broj odabran od 0 i 1;
ili njegova sol.
8. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da
prsten A je
[image]
R1 se bira iz skupine koju čine H, F, Cl, Br, CN, -OH, C1-4-alkil, -O-(C1-4-alkil), -C(=O)-NH2, -C(=O)-NH-(C1-4-alkil), -C(=O)-N(C1-4-alkil)2 i heterociklil,
pri čemu je svaka alkil skupina ili podskupina opcionalno supstituirana s jednim ili više F atoma ili s jednom OH ili -O-(C1-3-alkil) skupinom; i
pri čemu se svaki heterociklil bira iz skupine koju čine azetidinil, i piperidinil, i opcionalno je supstituiran s jednom C1-3-alkil, -C(=O)-CH3 ili -C(=O)-ciklopropil skupinom; i
gdje, ako n je 2, višestruki R1 mogu biti isti ili različiti i druga R1 skupina se bira iz skupine koju čine F i CH3; i
n je cijeli broj odabran od 1 i 2;
ili njegova sol.
9. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da se bira iz skupine koju čine:
[image]
[image]
[image]
ili njegova sol.
10. Spoj formule (I) prema patentnom zahtjevu 9, naznačen time, da ima sljedeću strukturu:
[image]
11. Spoj formule (I) prema patentnom zahtjevu 9, naznačen time, da ima sljedeću strukturu:
[image]
12. Spoj formule (I) prema patentnom zahtjevu 9, naznačen time, da ima sljedeću strukturu:
[image]
13. Spoj formule (I) prema patentnom zahtjevu 9, naznačen time, da ima sljedeću strukturu:
[image]
14. Spoj formule (I) prema patentnom zahtjevu 9, naznačen time, da ima sljedeću strukturu:
[image]
15. Spoj formule (I) prema patentnom zahtjevu 9, naznačen time, da ima sljedeću strukturu:
[image]
16. Farmaceutski prihvatljiva sol, naznačena time, da je od spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 15.
17. Spoj prema bilo kojem od patentnih zahtjeva 1 do 15, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu kao lijek.
18. Spoj prema bilo kojem od patentnih zahtjeva 1 do 15, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u liječenju raka, NASH (nealkoholnog steatohepatitisa), plućne fibroze, retinopatije, nefropatije ili moždanog udara.
19. Farmaceutski pripravak, naznačen time, da sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 15 ili njegovu farmaceutski prihvatljivu sol, opcionalno zajedno s jednim ili više inertnih nosača i/ili razrjeđivača.
20. Farmaceutski pripravak, naznačen time, da sadrži jedan ili više spojeva u skladu s jednim ili više od patentnih zahtjeva 1 do 15 ili njihove farmaceutski prihvatljive soli, te jedno ili više dodatnih terapijskih sredstava, opcionalno zajedno s jednim ili više inertnih nosača i/ili razrjeđivača.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203196 | 2018-10-29 | ||
| EP19794970.4A EP3873600B9 (en) | 2018-10-29 | 2019-10-24 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| PCT/EP2019/078992 WO2020089026A1 (en) | 2018-10-29 | 2019-10-24 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231608T1 true HRP20231608T1 (hr) | 2024-03-15 |
Family
ID=64082994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231608TT HRP20231608T1 (hr) | 2018-10-29 | 2019-10-24 | Derivati piridinil sulfonamida, njihovi farmaceutski pripravci i njihove uporabe |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20210361637A1 (hr) |
| EP (1) | EP3873600B9 (hr) |
| JP (1) | JP7317109B2 (hr) |
| KR (1) | KR20210084537A (hr) |
| CN (1) | CN112955215B (hr) |
| AU (1) | AU2019373306B2 (hr) |
| BR (1) | BR112021004635A2 (hr) |
| CA (1) | CA3112510A1 (hr) |
| CL (1) | CL2021000839A1 (hr) |
| CO (1) | CO2021005509A2 (hr) |
| CR (1) | CR20210216A (hr) |
| DK (1) | DK3873600T5 (hr) |
| DO (1) | DOP2021000068A (hr) |
| EA (1) | EA202191114A1 (hr) |
| EC (1) | ECSP21030482A (hr) |
| ES (1) | ES2967359T3 (hr) |
| FI (1) | FI3873600T3 (hr) |
| HR (1) | HRP20231608T1 (hr) |
| HU (1) | HUE064995T2 (hr) |
| IL (1) | IL282428A (hr) |
| LT (1) | LT3873600T (hr) |
| MA (1) | MA54051A (hr) |
| MX (1) | MX2021004940A (hr) |
| PE (1) | PE20211467A1 (hr) |
| PL (1) | PL3873600T3 (hr) |
| PT (1) | PT3873600T (hr) |
| RS (1) | RS64963B1 (hr) |
| SA (1) | SA521421755B1 (hr) |
| SG (1) | SG11202102440SA (hr) |
| SI (1) | SI3873600T1 (hr) |
| WO (1) | WO2020089026A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210353608A1 (en) * | 2018-10-29 | 2021-11-18 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| BR112022004451A2 (pt) | 2019-09-13 | 2022-06-21 | Nimbus Saturn Inc | Antagonistas de hpk1 e usos dos mesmos |
| CN114621189B (zh) * | 2020-12-14 | 2024-01-02 | 上海拓界生物医药科技有限公司 | 一种内酰胺类衍生物及其用途 |
| CN114621243B (zh) * | 2020-12-14 | 2024-03-01 | 上海拓界生物医药科技有限公司 | 一种磺酰胺类衍生物及其用途 |
| CN114621190B (zh) * | 2020-12-14 | 2023-12-05 | 上海拓界生物医药科技有限公司 | 一种烯丙基胺类衍生物及其用途 |
| WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1119344C (zh) | 1996-12-19 | 2003-08-27 | 阿旺蒂斯制药公司 | 杂环取代的新型吡咯烷酰胺衍生物 |
| CL2007003580A1 (es) | 2006-12-11 | 2009-03-27 | Boehringer Ingelheim Int | Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes. |
| US9192617B2 (en) * | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN107266332B (zh) | 2012-05-02 | 2020-07-24 | 勃林格殷格翰国际有限公司 | Ssao的取代的3-卤代烯丙基胺抑制剂及其用途 |
| MX2018013701A (es) * | 2016-05-12 | 2019-05-02 | Boehringer Ingelheim Int | Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3. |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| US20210353608A1 (en) * | 2018-10-29 | 2021-11-18 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
-
2019
- 2019-10-24 SG SG11202102440SA patent/SG11202102440SA/en unknown
- 2019-10-24 LT LTEPPCT/EP2019/078992T patent/LT3873600T/lt unknown
- 2019-10-24 AU AU2019373306A patent/AU2019373306B2/en active Active
- 2019-10-24 PT PT197949704T patent/PT3873600T/pt unknown
- 2019-10-24 MA MA054051A patent/MA54051A/fr unknown
- 2019-10-24 CA CA3112510A patent/CA3112510A1/en active Pending
- 2019-10-24 MX MX2021004940A patent/MX2021004940A/es unknown
- 2019-10-24 CR CR20210216A patent/CR20210216A/es unknown
- 2019-10-24 BR BR112021004635-6A patent/BR112021004635A2/pt unknown
- 2019-10-24 FI FIEP19794970.4T patent/FI3873600T3/fi active
- 2019-10-24 DK DK19794970.4T patent/DK3873600T5/da active
- 2019-10-24 SI SI201930672T patent/SI3873600T1/sl unknown
- 2019-10-24 PE PE2021000602A patent/PE20211467A1/es unknown
- 2019-10-24 EP EP19794970.4A patent/EP3873600B9/en active Active
- 2019-10-24 US US17/285,918 patent/US20210361637A1/en active Pending
- 2019-10-24 WO PCT/EP2019/078992 patent/WO2020089026A1/en active Application Filing
- 2019-10-24 EA EA202191114A patent/EA202191114A1/ru unknown
- 2019-10-24 PL PL19794970.4T patent/PL3873600T3/pl unknown
- 2019-10-24 JP JP2021523407A patent/JP7317109B2/ja active Active
- 2019-10-24 RS RS20231203A patent/RS64963B1/sr unknown
- 2019-10-24 CN CN201980071238.4A patent/CN112955215B/zh active Active
- 2019-10-24 ES ES19794970T patent/ES2967359T3/es active Active
- 2019-10-24 HU HUE19794970A patent/HUE064995T2/hu unknown
- 2019-10-24 KR KR1020217015606A patent/KR20210084537A/ko not_active Application Discontinuation
- 2019-10-24 HR HRP20231608TT patent/HRP20231608T1/hr unknown
-
2021
- 2021-04-05 CL CL2021000839A patent/CL2021000839A1/es unknown
- 2021-04-14 SA SA521421755A patent/SA521421755B1/ar unknown
- 2021-04-16 DO DO2021000068A patent/DOP2021000068A/es unknown
- 2021-04-19 IL IL282428A patent/IL282428A/en unknown
- 2021-04-27 CO CONC2021/0005509A patent/CO2021005509A2/es unknown
- 2021-04-28 EC ECSENADI202130482A patent/ECSP21030482A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231608T1 (hr) | Derivati piridinil sulfonamida, njihovi farmaceutski pripravci i njihove uporabe | |
| HRP20230233T1 (hr) | Inhibitori pirazola magl | |
| HRP20201934T1 (hr) | Anti-fibrotički piridinoni | |
| CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| HRP20171258T1 (hr) | Acilamino-supstituirani kondenzirani derivati ciklopentankarboksilne kiseline i njihova upotreba kao farmaceutski proizvodi | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| JP2018535963A5 (hr) | ||
| HRP20160292T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| CA2495880A1 (en) | Pyrimidine derivatives and their use as cb2 modulators | |
| HRP20151250T1 (hr) | Derivati izoksazolo-piridina | |
| ATE131479T1 (de) | 1,3-dihydro-2h-imidano 4,5-b-quinolin-2-ein derivate als phosphodiestenase hemmer | |
| AR068054A1 (es) | Compuestos de pirrolopirimidina | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| HRP20130976T1 (hr) | Karbonilaminopirolopirazoli, potentni inhibitori kinaza | |
| CA2574600A1 (en) | Pyridine derivatives | |
| AR055041A1 (es) | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| BRPI0907122B8 (pt) | compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos | |
| RU2006139140A (ru) | Средства и способы для лечения нарушений свертываемости | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| HRP20110624T1 (hr) | Supstituirani piperazinilpirazini kao antagonisti receptora 5-ht7 | |
| HRP20181027T1 (hr) | Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a | |
| RS53277B (en) | TRANSPORTER INHIBITORS-1 GLYCINE | |
| AR064481A1 (es) | Derivados de espiro-piperidina |